{"schema_version":"1","generated_at":"2026-11-01T09:56:09.304Z","data_as_of":null,"url":"https://www.findmykol.com/kol/avina-singh","json_url":"https://www.findmykol.com/kol/avina-singh/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"avina-singh","name":"Avina Singh","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"Metro-Minnesota Community Oncology Research Consortium","institution_url":"https://www.findmykol.com/institution/metro-minnesota-community-oncology-research-consortium","city":"Burnsville","state":"MN","region":{"label":"Midwest","url":"https://www.findmykol.com/region/midwest"}},"identifiers":{"npi":"1821201666","openalex":"A5076827443"},"summary":"Avina Singh is an Oncology physician affiliated with Metro-Minnesota Community Oncology Research Consortium. OpenAlex indexes 8 publications with 1,583 citations (h-index 7).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":8,"cited_by_count":1583,"h_index":7,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":3,"program_years":{"first":2021,"last":null},"rows_total":3,"shown":3,"withheld":0,"rows":[{"payer":"Allergan, Inc.","program_year":2022,"amount_usd":120,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1821201666"},{"payer":"E.R. Squibb & Sons, L.L.C.","program_year":2022,"amount_usd":22.2,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1821201666"},{"payer":"Gilead Sciences, Inc.","program_year":2021,"amount_usd":11.92,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1821201666"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1821201666","source":"payments"},"prescribing":{"data_year":2024,"areas_total":10,"areas_shown":3,"areas":[{"area":"Metabolism & gastrointestinal","share_pct":41.2,"classes_total":6,"classes":[{"class":"Substance P/Neurokinin-1 Receptor Antagonist","setting":"administered","share_pct":36.7,"drugs":[{"name":"Aprepitant","share_pct":100}],"max_beneficiaries":36},{"class":"Serotonin-3 Receptor Antagonist","setting":"mixed","share_pct":4.3,"drugs":[{"name":"Palonosetron hcl","share_pct":72.3},{"name":"Granisetron hydrochloride","share_pct":27},{"name":"Ondansetron Hcl","share_pct":0.7}],"max_beneficiaries":null}]},{"area":"Cancer & immunology","share_pct":30.3,"classes_total":12,"classes":[{"class":"PD-1 inhibitor","setting":"administered","share_pct":26.9,"drugs":[{"name":"Pembrolizumab","share_pct":100}],"max_beneficiaries":18},{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":1.2,"drugs":[{"name":"Letrozole","share_pct":62.5},{"name":"Anastrozole","share_pct":31.7},{"name":"Exemestane","share_pct":5.7}],"max_beneficiaries":102}]},{"area":"Blood & clotting","share_pct":17.2,"classes_total":3,"classes":[{"class":"Erythropoiesis-stimulating Agent","setting":"administered","share_pct":16.9,"drugs":[{"name":"Darbepoetin alfa","share_pct":100}],"max_beneficiaries":11},{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":0.2,"drugs":[{"name":"Xarelto","share_pct":51.4},{"name":"Eliquis","share_pct":48.6}],"max_beneficiaries":16}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"publications":{"total":8,"shown":5,"withheld":3,"matched_by":"OpenAlex author record","recent":[{"title":"Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2024013474","status":"verified"},{"title":"Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma","year":2024,"journal":"New England Journal of Medicine","source_url":"https://doi.org/10.1056/nejmoa2405888","status":"verified"},{"title":"Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","year":2022,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2021014960","status":"verified"},{"title":"Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib","year":2021,"journal":"Blood","source_url":"https://doi.org/10.1182/blood.2020010146","status":"verified"},{"title":"Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912","year":2021,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2021-150462","status":"verified"}],"source":"works"},"contact":{"address_1":"675 E NICOLLET BLVD STE 100","city":"Burnsville","state":"MN","zip":"553376749","phone":"952-892-7190","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1821201666","source":"identity"},"similar":[{"name":"Thomas Amatruda","slug":"thomas-amatruda","institution":"Metro-Minnesota Community Oncology Research Consortium","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/thomas-amatruda","json_url":"https://www.findmykol.com/kol/thomas-amatruda/profile.json"},{"name":"Robert Haselow","slug":"robert-haselow","institution":"Metro-Minnesota Community Oncology Research Consortium","specialty":"Radiation Oncology","url":"https://www.findmykol.com/kol/robert-haselow","json_url":"https://www.findmykol.com/kol/robert-haselow/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Larry Norton","slug":"larry-norton","institution":"Memorial Sloan Kettering Cancer Center","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/larry-norton","json_url":"https://www.findmykol.com/kol/larry-norton/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":3}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2018-02-21","collected_at":"2026-10-31T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}